MRI contrast agent developer Epix Medical reported revenues of $2.3 million in its second quarter, compared with the $267,000 posted for the same quarter in 1999. The Cambridge, MA-based vendor had a net loss of $4.6 million during the period (end-June 30), compared with a net loss of $4 million in the same quarter last year.
By AuntMinnie.com staff writersJuly 21, 2000
Related Reading
Schering, Epix, Mallinckrodt exchange rights for cardiac MRI agent, June 9, 2000.
Epix, Schering end patent dispute, May 9, 2000.
Copyright © 2000 AuntMinnie.com